LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Carbone, Erica J.; Rajpura, Komal; Laurencin, Cato T.; Lo, Kevin W.-H.; Jiang, Tao (2014)
Publisher: Advances in Regenerative Biology
Journal: Advances in Regenerative Biology
Languages: English
Types: Article
Subjects: small molecules, bone regeneration, drug discovery, regenerative engineering
Stimulation of bone formation using recombinant growth factors has been a promising strategy for bone repair and regeneration. However, small molecules have been suggested as alternatives to recombinant protein-based treatments because of their unique advantages. To date, therapeutic methods for orthopaedic applications still heavily rely on therapeutic protein-based growth factors. This trend is likely to be reversed since innovative drug discovery strategies, such as broad-spectrum database analysis and high throughput functional screens, have led to the discovery of many novel small molecule compounds and the development of novel applications of existing approved small molecule compounds. It should be noted that some of these small molecules with osteoinductive potential have been approved for human use due to their efficacy in treating other health ailments. Thus, these approved small molecule compounds are highly translatable to orthopaedic applications. In this article, we review the literature, paying attention to the prospects of existing approved small molecule therapeutics with bone regenerative capacity. Future directions of bone repair and regeneration using these approved small molecule drugs will be discussed as well.Keywords: small molecules; bone regeneration; drug discovery(Published: 26 September 2014)Citation: Advances in Regenerative Biology 2014, 1: 25276 - http://dx.doi.org/10.3402/arb.v1.25276Abstract in popular scienceSkeletal diseases and injuries, such as bone fractures, affect a significant portion of the population. While several protein-based medications are currently approved for the treatment of skeletal disorders via bone repair and regeneration, it is known that these protein-based therapeutics can cause significant side-effects. An alternative to protein-based pharmaceuticals is urgently needed in order for the therapeutics to be safer, more effective, and more affordable. Small molecule-based drugs are more appealing for treating bone diseases because they are more affordable, more stable, and require a smaller dosage to achieve a bone regenerative effect. Interestingly, some small molecule drugs that are already being prescribed to treat a variety of medical conditions have shown potential to be used as therapeutics for bone repair and regeneration. This review article provides a summary of recent findings of approved small molecule compounds with bone regenerative capability.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J Tissue Eng Regen Med. 2008; 2: 81 96.
    • 2. Lo KW-H, Ulery BD, Ashe KM, Laurencin CT. Studies of bone morphogenetic protein-based surgical repair. Adv Drug Deliv Rev. 2012; 64: 1277 91.
    • 3. Urist MR. Bone: formation by autoinduction. Science. 1965; 150: 893 9.
    • 4. Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts). J Tissue Eng Regen Med. 2008; 2: 1 13.
    • 5. Lo KW-H, Ashe KM, Kan HM, Laurencin CT. The role of small molecules in the musculoskeletal regeneration. Regen Med. 2012; 7: 535 49.
    • 6. Lo KW-H, Jiang T, Gagnon KA, Nelson C, Laurencin CT. Small molecule based musculoskeletal regenerative engineering. Trends Biotechnol. 2014; 32: 74 81.
    • 7. Langle D, Halver J, Rathmer B, Willems E, Schade D. Small molecules targeting in vivo tissue regeneration. ACS Chem Biol. 2014; 9: 57 71.
    • 8. Lyssiotis CA, Lairson LL, Boitano AE, Wurdak H, Zhu S, Schultz PG. Chemical control of stem cell fate and developmental potential. Angew Chem Int Ed Engl. 2011; 50: 200 42.
    • 9. Laurencin CT, Ashe KM, Henry N, Kan HM, Lo KWH. Delivery of small molecules for bone regenerative engineering: preclinical studies and potential clinical applications. Drug Discov Today. 2014; 19: 794 800. DOI: 10.1016/j.drudis.2014. 01.012.
    • 10. Carbone EJ, Jiang T, Nelson C, Henry N, Lo KW. Small molecule delivery through nanofibrous scaffolds for musculoskeletal regenerative engineering. Nanomedicine. 2014. DOI: 10.1016/j.nano.2014.05.013. [Epub ahead of print].
    • 11. Egusa H, Saeki M, Doi M, Fukuyasu S, Matsumoto T, Kamisaki Y, et al. A small-molecule approach to bone regenerative medicine in dentistry. J Oral Biosci. 2010; 52: 107 18.
    • 12. Segar CE, Ogle ME, Botchwey EA. Regulation of angiogenesis and bone regeneration with natural and synthetic small molecules. Curr Pharm Des. 2013; 19: 3403 19.
    • 13. Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014; 88C: 3 11.
    • 14. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999; 286: 1946 9.
    • 15. Pagkalos J, Cha JM, Kang Y, Heliotis M, Tsiridis E, Mantalaris A. Simvastatin induces osteogenic differentiation of murine embryonic stem cells. J Bone Miner Res. 2010; 25: 2470 8.
    • 16. Park JB. The use of simvastatin in bone regeneration. Med Oral Patol Oral Cir Bucal. 2009; 14: e485 8.
    • 17. Morris CD, Einhorn TA. Bisphosphonates in orthopaedic surgery. J Bone Joint Surg Am. 2005; 87: 1609 18.
    • 18. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996; 97: 2692 6.
    • 19. Wang CZ, Chen SM, Chen CH, Wang CK, Wang GJ, Chang JK, et al. The effect of the local delivery of alendronate on human adipose-derived stem cell-based bone regeneration. Biomaterials. 2010; 31: 8674 83.
    • 20. Bobyn JD, Thompson R, Lim L, Pura JA, Bobyn K, Tanzer M. Local alendronic acid elution increases net periimplant bone formation: a micro-CT analysis. Clin Orthop Relat Res. 2014; 472: 687 94.
    • 21. Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Montagnani A, Monaco R, et al. Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int. 1999; 65: 359 64.
    • 22. Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res. 1994; 9: 1833 7.
    • 23. Zhang C, Duvic M. Treatment of cutaneous T-cell lymphoma with retinoids. Dermatol Ther. 2006; 19: 264 71.
    • 24. Mongan NP, Gudas LJ. Diverse actions of retinoid receptors in cancer prevention and treatment. Differentiation. 2007; 75: 853 70.
    • 25. Mitra A, Wu Y. Topical delivery for the treatment of psoriasis. Expert Opin Drug Deliv. 2010; 7: 977 92.
    • 26. Micali G, Lacarrubba F, Nasca MR, Schwartz RA. Topical pharmacotherapy for skin cancer: part I. Pharmacology. J Am Acad Dermatol. 2014; 70: 965 e1 12.
    • 27. Wan DC, Siedhoff MT, Kwan MD, Nacamuli RP, Wu BM, Longaker MT. Refining retinoic acid stimulation for osteogenic differentiation of murine adipose-derived adult stromal cells. Tissue Eng. 2007; 13: 1623 31.
    • 28. Bi W, Gu Z, Zheng Y, Wang L, Guo J, Wu G. Antagonistic and synergistic effects of bone morphogenetic protein 2/7 and alltrans retinoic acid on the osteogenic differentiation of rat bone marrow stromal cells. Dev Growth Differ. 2013; 55: 744 54.
    • 29. James AW, Levi B, Xu Y, Carre AL, Longaker MT. Retinoic acid enhances osteogenesis in cranial suture-derived mesenchymal cells: potential mechanisms of retinoid-induced craniosynostosis. Plast Reconstr Surg. 2010; 125: 1352 61.
    • 30. Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol. 2005; 56: 47 60.
    • 31. Lee KW, Yook JY, Son MY, Kim MJ, Koo DB, Han YM, et al. Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway. Stem Cells Dev. 2010; 19: 557 68.
    • 32. Singha UK, Jiang Y, Yu S, Luo M, Lu Y, Zhang J, et al. Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells. J Cell Biochem. 2008; 103: 434 46.
    • 33. Byun YK, Kim KH, Kim SH, Kim YS, Koo KT, Kim TI, et al. Effects of immunosuppressants, FK506 and cyclosporin A, on the osteogenic differentiation of rat mesenchymal stem cells. J Periodontal Implant Sci. 2012; 42: 73 80.
    • 34. Cvetkovic M, Mann GN, Romero DF, Liang XG, Ma Y, Jee WS, et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation. 1994; 57: 1231 7.
    • 35. Stempfle HU, Werner C, Siebert U, Assum T, Wehr U, Rambeck WA, et al. The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, doubleblind trial with calcitriol. Transplantation. 2002; 73: 547 52.
    • 36. Kaihara S, Bessho K, Okubo Y, Sonobe J, Kawai M, Iizuka T. Simple and effective osteoinductive gene therapy by local injection of a bone morphogenetic protein-2-expressing recombinant adenoviral vector and FK506 mixture in rats. Gene Ther. 2004; 11: 439 47.
    • 37. Tang L, Ebara S, Kawasaki S, Wakabayashi S, Nikaido T, Takaoka K. FK506 enhanced osteoblastic differentiation in mesenchymal cells. Cell Biol Int. 2002; 26: 75 84.
    • 38. Kugimiya F, Yano F, Ohba S, Igawa K, Nakamura K, Kawaguchi H, et al. Mechanism of osteogenic induction by FK506 via BMP/Smad pathways. Biochem Biophys Res Commun. 2005; 338: 872 9.
    • 39. Eglence A, Colterjohn N, Duivenvoorden WCM, Ghert M, Singh G. Effect of bone morphogenetic protein-2 and doxycycline on the differentiation of osteoprogenitors from human femoral bone. Open Bone J. 2009; 1: 1 7.
    • 40. Kaur K, Sikri P. Evaluation of the effect of allograft with doxycycline versus the allograft alone in the treatment of infrabony defects: a controlled clinical and radiographical study. Dent Res J (Isfahan) 2013; 10: 238 46.
    • 41. Walter MS, Frank MJ, Satue M, Monjo M, Ronold HJ, Lyngstadaas SP, et al. Bioactive implant surface with electrochemically bound doxycycline promotes bone formation markers in vitro and in vivo. Dent Mater. 2014; 30: 200 14.
    • 42. Giger EV, Castagner B, Leroux JC. Biomedical applications of bisphosphonates. J Control Release. 2013; 167: 175 88.
    • 43. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008; 19: 733 59.
    • 44. Zhang S, Gangal G, Uludag H. 'Magic bullets' for bone diseases: progress in rational design of bone-seeking medicinal agents. Chem Soc Rev. 2007; 36: 507 31.
    • 45. Song HM, Nacamuli RP, Xia W, Bari AS, Shi YY, Fang TD, et al. High-dose retinoic acid modulates rat calvarial osteoblast biology. J Cell Physiol. 2005; 202: 255 62.
    • 46. Maeda T, Matsunuma A, Kawane T, Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun. 2001; 280: 874 7.
    • 47. Baek KH, Lee WY, Oh KW, Tae HJ, Lee JM, Lee EJ, et al. The effect of simvastatin on the proliferation and differentiation of human bone marrow stromal cells. J Korean Med Sci. 2005; 20: 438 44.
    • 48. Ruiz-Gaspa S, Nogues X, Enjuanes A, Monllau JC, Blanch J, Carreras R, et al. Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J Cell Biochem. 2007; 101: 1430 8.
    • 49. Dai W, Dong J, Fang T, Uemura T. Stimulation of osteogenic activity in mesenchymal stem cells by FK506. J Biomed Mater Res A. 2008; 86: 235 43.
    • 50. Holstein JH, Klein M, Garcia P, Histing T, Culemann U, Pizanis A, et al. Rapamycin affects early fracture healing in mice. Br J Pharmacol. 2008; 154: 1055 62.
    • 51. Ogawa T, Tokuda M, Tomizawa K, Matsui H, Itano T, Konishi R, et al. Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteosarcoma (ROS 17/2.8) cells. Biochem Biophys Res Commun. 1998; 249: 226 30.
    • 52. Griffin MO, Fricovsky E, Ceballos G, Villarreal F. Tetracyclines: a pleiotropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol. 2010; 299: C539 48.
    • 53. Mostafa NZ, Fitzsimmons R, Major PW, Adesida A, Jomha N, Jiang H, et al. Osteogenic differentiation of human mesenchymal stem cells cultured with dexamethasone, vitamin D3, basic fibroblast growth factor, and bone morphogenetic protein-2. Connect Tissue Res. 2012; 53: 117 31.
    • 54. Liu YC, Kao YT, Huang WK, Lin KY, Wu SC, Hus SC, et al. CCL5/RANTES is important for inducing osteogenesis of human mesenchymal stem cells and is regulated by dexamethasone. BioSci Trends. 2014; 8: 138 43.
    • 55. Igarashi M, Kamiya N, Hasegawa M, Kasuya T, Takahashi T, Takagi M. Inductive effects of dexamethasone on the gene expression of Cbfa1, Osterix and bone matrix proteins during differentiation of cultured primary rat osteoblasts. J Mol Histol. 2004; 35: 3 10.
    • 56. Piao ZG, Kim JS, Son JS, Lee SY, Fang XH, Oh JS, et al. Osteogenic evaluation of collagen membrane containing drugloaded polymeric microparticles in a rat calvarial defect model. Tissue Eng Part A. 2014. DOI: 10.1089/ten.tea.2013.0717. [Epub ahead of print].
    • 57. Fiorentini E, Granchi D, Leonardi E, Baldini N, Ciapetti G. Effects of osteogenic differentiation inducers on in vitro expanded adult mesenchymal stromal cells. Int J Artif Organs. 2013; 34: 998 1011.
    • 58. Hadzir SN, Ibrahim SN, Abdul Wahab RM, Zainol Abidin IZ, Senafi S, Ariffin ZZ, et al. Ascorbic acid induces osteoblast differentiation of human suspension mononuclear cells. Cytotherapy. 2014; 16: 674 82.
    • 59. Zhu LL, Cao J, Sun M, Yuen T, Zhou R, Li J, et al. Vitamin C prevents hypogonadal bone loss. PLoS One. 2012; 7: e47058.
    • 60. Logovskaya LV, Bukharova TB, Volkov AV, Vikhrova EB, Makhnach OV, Goldshtein DV. Induction of osteogenic differentiation of multipotent mesenchymal stromal cells from human adipose tissue. Bull Exp Biol Med. 2013; 155: 145 50.
    • 61. Nakanishi T, Saito R, Taniguchi M, Oda H, Soma A, Yasunaga M, et al. In vivo determination of vitamin d function using transgenic mice carrying a human osteocalcin luciferase reporter gene. Biomed Res Int. 2013; 2013: 895706.
  • No related research data.
  • No similar publications.

Share - Bookmark

Funded by projects

  • NIH | Engineered Regeneration of ...

Cite this article

Collected from